$UTHR News

United Therapeutics Corporation (UTHR) Presents at Jefferies Global Healthcare Conference 2026 Transcript

United Therapeutics Corporation (UTHR): Renaissance Technologies Likes This Biotech Stock

United Therapeutics Explores Pig Heart Transplants And Space Labs As Valuation Lags

United Therapeutics Corporation (UTHR) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

United Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026

United Therapeutics Says New England Journal Of Medicine Publishes Full Results Of TETON-1 Study And Combined Analyses Of TETON-1, TETON-2 Studies, Evaluating Use Of Nebulized Tyvaso For Treatment Of IPF

MannKind Corp. (MNKD) Reports Q1 2026 Total Revenues of $90.2M

United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026

5 Insightful Analyst Questions From United Therapeutics’s Q1 Earnings Call

United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial

United Therapeutics Reveals FDA Clearance To Proceed With UHeart Xenotransplantation Clinical Trial

Space-Based Pulmonary Drug Formulation Might Change The Case For Investing In United Therapeutics (UTHR)

CPRX or UTHR: Which Is the Better Value Stock Right Now?

Varda Space Industries and United Therapeutics Collaborate to Advance Microgravity-Enabled Treatments for Rare Pulmonary Disease

United Therapeutics Enters Collaboration With Varda Space Industries To Explore The Use Of Microgravity To Develop Treatments For Rare Pulmonary Disease

United Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference

Why This Biotech Stock Just Broke Out To A Record High

United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026

United Therapeutics Announces 12 New Data Presentations Across Its Commercial And Development Portfolio For The American Thoracic Society Conference, May 15-20

MannKind (MNKD) Is Up 25.4% After Mixed Q1 Results and Expanded United Therapeutics Partnership – What's Changed